



Christine C. Vito, Ph.D.

Senior Of Counsel

Boston
+1.617.261.3150

christine.vito@klgates.com

OVERVIEW

Dr. Christine Vito is a partner in the intellectual property practice group at K&L Gates. She advises clients in all matters relating to patent procurement and strategic portfolio development; technology licensing and asset management; and, general intellectual property counseling regarding patent infringement, validity and enforcement. Dr. Christine's practice concentrates on the life/medical sciences and biotechnology, and her clients include venture-backed companies, multi-national corporations, venture firms, non-profit organizations, and universities. Dr. Christine was named among the "Best Lawyers in America in Biotechnology Law" in *IP Law & Business*. Dr. Christine has been selected by her peers for inclusion in the 2011, 2013, 2014, 2015, and 2016 editions of *The Best Lawyers in America*® in the practice area of Biotechnology Law. Recently, she was again selected as an IP Star by *Managing IP* for 2016.

PROFESSIONAL BACKGROUND

Prior to joining K&L Gates, Dr. Christine was a partner in the patent and intellectual property practice group of Testa, Hurwitz & Thibault, LLP. She was previously a scientist in both the academic and industry sectors. While at Children's Hospital and Harvard Medical School in Boston, Dr. Christine studied developmental neuroendocrinology and collaborated with many of the field's leading behavioral biologists. After leaving academia, Dr. Christine joined Ventrex Laboratory of Portland, Maine, where she served as Manager of Scientific Affairs and coordinator of technology-related legal matters, including patent matters. From 1989-1993, she was a member of the Maine State Commission on Biotechnology and Genetic Engineering.

ACHIEVEMENTS

- Recognized in the inaugural edition of *Managing Intellectual Property - IP Stars* as one of the "Top 250 Women in IP 2013"
- Listed in the *Best Lawyers in America* for Biotechnology and Life Sciences, 2008-2019
- Selected for inclusion in *The Best Lawyers in America*® - Biotechnology, 2016.
- Selected as an IP Star by *Managing IP*, for both Massachusetts and the U.S., 2014-2018

PROFESSIONAL / CIVIC ACTIVITIES

- American Bar Association – Intellectual Property Section Member
- American Intellectual Property Law Association
- Massachusetts Bar Association
- Maine Bar Association

EDUCATION

- J.D., University of Maine School of Law, 1993 (*cum laude*; *Production Editor, The Maine Law Review*)
- Ph.D., University of Massachusetts at Amherst, 1976 (*Microbiology*)
- B.A., University of Massachusetts, 1970

ADMISSIONS

- Bar of Maine
- Bar of Massachusetts
- United States Patent and Trademark Office
- United States District Court for the District of Massachusetts

OTHER PUBLICATIONS

- "Intellectual Property Considerations for Medical Device Companies," in *Medical Devices law and Regulation Answer Book 2011-12* (Eds. S. Onel & K.M. Becker), Practising Law Institute, NYC, NY (2011), Moore, R.P. and Vito, C.C.
- "Managing Innovation: Patent Basics for Biotechnology Counsel," in *Biotechnology and the Law*, (ABA Publishing, 2007), M.H. Brodowski, T.A. Turano and C.C. Vito
- "The Good, Bad, and Ugly of Intellectual Property Due Diligence: The Do's and Don'ts," in *Intellectual Property Assets*, (MCLE, Inc. 2007), C.C. Vito
- "Intellectual Property Due Diligence: A Corporate State of Mind," in *How to Protect and Preserve Intellectual Property*, (MCLE, Inc. 2006), C.C. Vito and T.A. Turano
- "Technology Transfer from Universities Around the World," *Patent World*, February 2005, C. Thornham, A. Trenton, C.C. Vito and B.J. Weidemier
- "The Impact of Biotech Licensing," *Genetic Engineering News*, February 1, C.C. Vito and B.J. Weidemier
- "In the Beginning, There Is a License," *IP Observer*, Fall 2004, C.C. Vito and B.J. Weidemier

- "Going Global," IP Law and Business, September 2004, C.C. Vito
- "Protections Differ in United States, Europe, Japan; Companies Need To Know What Is Patentable Subject Matter in Each Jurisdiction," National Law Journal, May 31, 2004, C.C. Vito
- "Biotech Licensing Is the Fuel That is Driving Innovation," Boston Business Journal, March 12, 2004, C.C. Vito and B.J. Weidemier
- "Taking a Global View of a Life Sciences Company's Patent Position," Journal of Biolaw & Business 7:54-55 (2004), C.C. Vito and J.A. Camacho
- "Taking a Global View of a Life Sciences Company's Patent Position," Venture Update Summer 2003, C.C. Vito and J.A. Camacho
- "Harmony and Discord Among Patent Systems," in Protecting and Exploiting IP Assets Internationally, (MCLE, Inc. 2003), C.C. Vito and J.A. Camacho
- "A New Defense Against Patent Infringement: Prosecution Laches," IP Observer, Summer 2002, C.C. Vito and T.A. Turano
- "New Infringement Defense of Prosecution Laches," Patent Strategy and Management, volume 2, no. 10 (Feb. 2002), C.C. Vito and T.A. Turano
- Seide, R.K., Ayala, A., Pitcher, E.R., Rice, G.A., and Vito, C.C., "Claim Drafting and Prosecution with a View Towards Litigation" 1994 Basic Chemical and Biotechnology Patent Practice Seminar, American Intellectual Property Law Association, 1994.
- Pitcher, E.R. and Vito, C.C., (1994) "Limits of Claimability: What is the Enabled Scope of a Claim Vis-à-vis the Scope of Disclosure?," American Intellectual Property Law Association, Mid-Winter Meeting, Seventeenth Annual Institute, January 26-29, 1994 (Rancho Mirage, California).
- Vito, C.C. (1993) "State Biotechnology Oversight: The Juncture of Technology, Law and Public Policy," Maine Law Review, Volume 45, Number 2.
- Gulliver, J.W. and Vito, C.C., (Winter 1992/1993) "The EMF Debate Comes of Age – Now What?," Natural Resources & Environment.
- Miller, H.C. and Vito, C.C. (1989) "Action of a thymic cytokine, TsIF™, in reversing the autoimmune disease state of the MRL/1pr mouse," Molecular Biotherapeutics -1:213-217.
- Vito, C.C. (1987) "Serum-free Media: Recommendations for Evaluating Performance," BioTrack, volume 2, number 1: 1-3.
- Vito, C.C., Baum, M.J., Bloom, C. and Fox, T.O., (1985) "Androgen and estrogen receptors in perinatal ferret brain," Journal of Neuroscience 5: 268-274.
- Pomerantz, S.M., Fox, T.O., Scholl, S.A., Vito, C.C., and Goy, R.W., (1985) "Androgen and estrogen receptors in fetal Rhesus monkey brain and anterior pituitary," Endocrinology 116: 83-89.

- Vito, C.C., DeBold, J.F., and Fox, T.O., (1983) "Androgen and estrogen receptors in adult hamster brain," *Brain Research* 264: 132-137.
- Fox, T.O., Olsen, K.L., Vito, C.C. and Wieland, S.J., "Putative steroid receptors: Genetics and development," In *Molecular Genetic Neuroscience*, eds. F.O. Schmitt, S.J. Bird & F.E. Bloom, Raven Press, New York, 1982, pp. 289-306.
- Vito, C.C. and Fox, T.O., (1982) "Androgen and estrogen receptors in embryonic and neonatal rat brain," *Developmental Brain Research* 2: 97-110.
- Salhanick, A.R., Vito, C.C., Fox, T.O., and Callard, I/P., (1979) "Estrogen-binding proteins in the oviduct of the turtle, *Chrysemys picta*: Evidence for a receptor species," *Endocrinology* 105: 1388-1395
- Vito, C.C., Wieland, S.J. and Fox, T.O., (1979) "Androgen receptors exist throughout the "Critical Period" of brain sexual differentiation," *Nature* 282: 308-310.
- Fox, T.O., Bates, S.E., Vito, C.C., and Wieland, S.J., (1979) "Carrier protein effects on DNA-cellulose chromatography of putative steroid receptors," *Journal of Biological Chemistry* 254: 4963-4966.
- Vito, C.C. and Fox, T.O., (1979) "Embryonic rodent brain contains estrogen receptors," *Science* 204: 517-519.
- Fox, T.O., Vito, C.C. and Wieland, S.J., (1978) "Estrogen and androgen receptor proteins in embryonic and neonatal brain: Hypothesis for roles in sexual differentiation and behavior," *American Zoologist* 18: 525-538.
- Vito, C.C. and Dowell, C.E., (1976) "Novel replicative properties of a capsid mutant of bacteriophage phi-X174," *Journal of Virology* 18: 942-949.
- Vito, C.C., Primrose, S.B. and Dowell, C.E., (1975) "Growth of a capsid mutant of bacteriophage phi-X174 in a temperature-sensitive strain of *Escherichia coli*," *Journal of Virology* 15: 281-287.

AREAS OF FOCUS

- IP Procurement and Portfolio Management
- Pharma and BioPharma Litigation
- Post-Grant Patents